Plasma‐derived factor X concentrate compassionate use for hereditary factor X deficiency: Long‐term safety and efficacy in a retrospective data‐collection study

BACKGROUND: Coagadex is a high‐purity plasma‐derived factor X concentrate (pdFX) developed to treat hereditary factor X deficiency (FXD). OBJECTIVE: Evaluate the efficacy and safety of pdFX administered to patients with hereditary FXD. METHODS: This was an open‐label, multicenter, retrospective anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, James N., Liesner, Ri, Austin, Steven K., Kavakli, Kaan, Akanezi, Chioma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268662/
https://www.ncbi.nlm.nih.gov/pubmed/34263102
http://dx.doi.org/10.1002/rth2.12550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268662/
https://www.ncbi.nlm.nih.gov/pubmed/34263102
http://dx.doi.org/10.1002/rth2.12550

Ejemplares similares